Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22.
Neurology. 2019.
PMID: 31118245
Free PMC article.
Clinical Trial.